CATALOGUE

of China Pavilion

BIO Convention 2023

中国国际商会

China Chamber of International Commerce

contents

目录

About China Chamber of International Commerce

China Chamber of International Commerce (CCOIC) is a nationwide business organization in China, representing the most dynamic and internationalized Chinese companies of all sizes, sectors, and regions, as well as national and local non-governmental organizations.

CCOIC's mission is, in accordance with the laws and regulations of the People's Republic of China, to expand the international business relationship to the benefit of its membership and, more broadly, the Chinese economy. It favors constructive engagement with foreign countries to eliminate trade and investment barriers and develop a rules-based commercial environment; improvement of business self-regulation in China and representation of China in the setting of international business rules and standards; advocacy for members whenever the Chinese or foreign government makes decisions that crucially affect corporate interests; spreading of business expertise to the development of Chinese economy, international business cooperation and the growth and prosperity of less developed countries.

CCOIC is governed by a board of directors composed of over 100 distinguished corporate leaders. The current chair is Mr. Wan Jifei, Chairman of China Council for the Promotion of International Trade (CCPIT).

CCOIC served as the National Committee of International Chamber of Commerce (ICC) since China's entry into ICC in 1994. Headquartered in Beijing, CCOIC maintains a professional staff of policy experts, lawyers, trainers, event organizers, and communicators. Special initiatives covering banking rules, new energy, recycling resources, infrastructure, education and training, debt collection, and real estate mobilize the involvement and contribution of members with the backup of CCOIC branches and expert commissions.

CCOIC

中国国际商会简介

中国国际商会（China Chamber of International Commerce 简称 CCOIC ）是在中国从事国际商事活动的企业、团体和其他组织组成的国家级国际性会员制商会组织（民政部登记证号：社证字第 4768 号）。

1988 年，国务院批准成立中国国际商会。2007 年 12 月 24 日，中国国际商会在人民大会堂隆重召开了会员代表大会，近六百家会员代表出席会议。时任国务院副总理吴仪同志亲临大会并做重要讲话，勉励中国国际商会发挥自身优势，积极推动企业开展国际化经营；坚持市场导向，不断拓展新的业务领域。此次盛会标志着中国国际商会登上新的历史起点，步入新的发展阶段，踏上新的远大航程。

中国国际商会以为会员提供专属优质服务为宗旨，其职责是向国际组织和政府部门反映中国工商业界的利益诉求，参与国际经贸规则与惯例的制定和推广，促进国内外经贸交流与合作，提供法律服务、商务咨询、信息资讯和业务培训等服务，倡导社会责任与公益事业等。

中国国际商会于 1994 年代表中国加入了国际商业组织 --- 国际商会（International Chamber of Commerce 简称 ICC），国际商会中国国家委员会（The Affiliate of International Chamber of Commerce in China 简称 ICC CHINA）秘书局设在中国国际商会。中国国际商会在开展与国际商会（ICC）相关业务时，使用 ICC CHINA 的名义。中国国际商会组织会员单位，全面深入地参与国际商会的各种活动，利用国际商会的全球商业网络，同各国商界、政府相关机构以及国际组织建立广泛联系，促进中外企业的合作与交流，推动中国经济融入世界的进程。

China Pavilion plan

中国馆平面图



2285

过道



2275

迪必尔生物 Parallel-Bioreactor.com 2275-A

T&J Bio-engineering (Shanghai) Co., Ltd
迪必尔生物工程（上海）有限公司

Founded in 2012, T&J Bioengineering has become the leading provider of high-throughput parallel bioreactor systems in China. As of March 2023, the company has over 4000 units in operation throughout China, predominantly in research laboratories and production plants where automation features are obligatory.
With three state-of-the-art facilities in Shanghai and Shenzhen, T&J employs over 150 full-time staff. The Shanghai-based factories specialize in designing and manufacturing glass and single-use systems, as well as GMP-compliant pressure vessels (up to 20,000 Liters). In addition, T&J has recently opened a new site in Shenzhen, widely recognized as China's Silicon Valley, focusing on developing cutting-edge process analytical technologies including biosensors, software, and automation.

迪必尔生物是国内领先的智能生物反应器综合解决方案供应商，致力于将生物反应器工艺数据化、智能化，以及将过程分析技术 (PAT) 和一次性反应器技术，覆盖到从实验室到中试再到生产的所有规模，赋能生物制造产业。与此同时，迪必尔通过原有的高通量生物反应器技术和数字“云”技术结合，打造基于人工智能和大数据搭建的智能制造平台，大幅度提高科研人员开展实验研究的效率，加速生物工艺开发进度。

地址：上海市松江区明南路 8 号
ADD：No. 8 Mingnan Road, Songjiang District, Shanghai
电话 /Tel：+86-21- 57640001
邮箱 /E-mail：lishaoli@parallel-bioreactor.com
网址 /Website：www.parallel-bioreactor.com

THOUSAND OAKS 2275-B

Thousand Oaks Biologics Inc.
澳斯康生物（南通）股份有限公司

地址：江苏省南通市海门区海门科技园 A1 楼
ADD：Building A1, Haimen Biotech and Pharmaceutical Park, Nantong, Jiangsu, China
电话 /Tel：+86-513-68067603
邮箱 /E-mail：services@tobiopharm.com
网址 /Website：www.tobiopharm.com

Thousand Oaks Biologics Inc. (Hereinafter referred to as TOBio) is a CDMO enterprise integrating cell culture media, biopharmaceutical development and contract manufacturing related business. It providing customers with one-stop-shop service for biologics including druggability assessment, cell line development, process development and optimization, manufacturing services from early stage to commercial, IND filing and NDA filing, etc.
TOBio has extensive experience in development and manufacturing of monoclonal antibody (mAb), bispecific antibody (BsAb), antibody-drug conjugate (ADC), Fc fusion proteins, and other recombinant protein products in the field of therapeutic biological products. It has successfully delivered nearly 100 biologic CMC projects, TOBio is one of the few CDMO which has successfully passed the pre-approval registration of products and GMP compliance on-site inspection. TOBio industry-leading technical experts with many decades of CMC experience is one of the key drivers that enables accelerated project timelines and reduction of the costs for clients.
TOBio has the manufacturing capacity of 200L, 500L and 2,000L of Traditional Fed Batch and Intensified Fed Batch, as well as Concentrated Fed Batch and Perfusion technology in China. The drug product facilities currently capable of conducting liquid or lyophilized fills at varying clinical and commercial scales and utilizing a variety of container and closure system configurations that include vials, prefilled syringes. TOBio advanced CDMO platform with a complete quality management system can meet US FDA, EU EMA, China NMPA, and other countries' regulatory standards.

澳斯康生物致力于打造中国生物制药行业集培养基、CMC 开发、及委托生产于一体的 CDMO 企业，专注于生物制药生产相关业务，可为客户提供“细胞构建 – 工艺、制剂、分析方法开发 – GMP 生产及上市工艺验证 – IND&NDA 申报”的一站式服务。澳斯康生物拥有高质量的运营及技术团队，在生物制药工艺及产业化方面拥有多年的经验。澳斯康生物具备 200L、500L、2,000L 传统 Fed Batch 和 Intensified Fed Batch 生产能力，以及以灌流技术为基础的 Concentrated Fed Batch 和 Perfusion 培养技术，制剂生产车间配备西林瓶分装 / 冻干及预灌封注射器 / 卡式瓶分装能力，可为海内外客户同时进行多个品种的生产服务，具有先进的 CDMO 服务能力，多次通过中国 NMPA、欧盟 EMA 标准的质量审计，并已成功通过产品获批前注册和 GMP 符合性二合一现场核查。

凯斯艾生物 KCI BioTech 2275-C

KCI BIOTECH (SUZHOU)INC.

凯斯艾生物科技（苏州）有限公司

KCI Biotech (SUZHOU) Inc. (KCI), a preclinical Contract Research Organization (CRO) providing specialty preclinical pharmacology services in cardiovascular diseases, immune diseases, inflammatory diseases, metabolic diseases, urinary diseases, neuron diseases and oncology by using small (mice, rabbits , dogs, pigs, NHPs, guinea etc.) animal disease models. We also conduct adjacency studies in PK/PD, preliminary toxicology, BSL2/ABSL2 level facilities medical image, translational medicine and pathology.

凯斯艾生物科技（苏州）有限公司是一家为医药研发领域提供临床前药效及成药性评价技术服务的CRO公司。致力于建立小动物（大小鼠，兔，犬，猪，猴，豚鼠等）综合性临床前药效及成药性评价平台。在心血管疾病、免疫性疾病、炎症性疾病、代谢性疾病、泌尿系统疾病，神经疾病和肿瘤疾病等领域提供专业的临床前药理药效评价服务，以及 PK/PD、非 GLP 毒理学、BSL2/ABSL2 级实验设施、医学影像学、转化医学等病理研究服务。

地址：苏州工业园区金鸡湖大道 99 号苏州纳米城西北区 12 幢 501 室
ADD：Room 501, Building 12, Northwest District, Suzhou Nano City, No.99 Jinji Lake Avenue, Suzhou Industrial Park
电话 /Tel：+86-13524244224
邮箱 /E-mail：xiele@kcibiotech.com
网址 /Website：www.kcibiotech.com

湖北葛店人福药用辅料有限责任公司 HUBEI GEDIAN HUMANWELL PHARMACEUTICAL EXCIPIENTS CO., LTD. 2285-F

Hubei Gedian Humanwell Pharmaceutical Excipients Co., Ltd.

湖北葛店人福药用辅料有限责任公司

地址：湖北省鄂州市葛店经济技术开发区建设大道 199 号
ADD：No. 199, Jianshe Avenue, Gedian Economic and Technological Development Zone, Ezhou City, Hubei Province
电话 /Tel：+86-15926340195
传真 /Fax：+86-0711-3813176
邮箱 /E-mail：gdrfyfmkt@renfu.com.cn
网址 /Website：www.gdrfyf.cn

Hubei Gedian Humanwell Pharmaceutical Excipients Co., Ltd. (www.gdrfyf.cn) is a professional pharmaceutical excipient high-tech enterprise integrating R & D, production and sales under the listed company Humanwell Pharmaceutical (Group) Co., Ltd. (stock code: 600079.SH, Hubei Provincial Pharmaceutical Leading Enterprise, Top 20 Pharmaceutical Industry of China). The company has passed ISO9001, ISO1400, ISO45001, GMP and CNAS (China National Accreditation Service for Conformity Assessment). The company has built lots of cGMP-compliant pharmaceutical excipient production workshops to meet the production of conventional, high-risk and biological pharmaceutical excipients. According to CP/EP/USP/JP, various products have been manufactured and registered with DMF in US FDA .

- 4 core technology platforms:

★ Oil esterification and purification technology
★ Polymerisation technology
★ Green synthesis technology
★ Small molecule purification technology

- Core products

★ Protein protectants: Polysorbate 20/80 (for injection), Poloxamer 188
★ Stabilizers: Sucrose (Low Endotoxin), Trehalose (Low Endotoxin)
★ Biological buffers: Trometamol, Trometamol hydrochloride
★ Core components of vaccine adjuvants: Squalene, Cholesterol, All-rac-α-Tocopherol
★ Adjuvants: RFH01, RFH02A/B, RFA01
★ Characteristic oils pharmaceutical excipients: Castor Oil（refined）, Sesame Oil（refined）, Omega-3-Acid Ethyl Ethers 90, Phospholipids For Injection, Synthetic glyceride
★ Other pharmaceutical excipients: Betadex Sulfobutyl Ether Sodium, Benzalkonium Chloride, Croscarmellose Sodium

湖北葛店人福药用辅料有限责任公司（www.gdrfyf.cn）是人福医药集团（股票代码：600079.SH，湖北省医药龙头企业，中国医药工业二十强）旗下集研发、生产、销售于一体的高端药用辅料高新技术企业。公司已通过 ISO9001、ISO1400、ISO45001、GMP 和 CNAS（China National Accreditation Service for Conformity Assessment）等认证。建有多个符合 cGMP 的药用辅料生产车间，满足常规、高风险用途和生物制剂药用辅料的生产。依据 CP、EP、USP、JP 要求，多个产品已在美国食品药物管理局（U.S. Food and Drug Administration, FDA）备案。

昭衍 JOINN 2275-E

JOINN Laboratories (Suzhou) Co., Ltd.
昭衍（苏州）新药研究中心有限公司

JOINN Laboratories is dedicated to providing drug R&D CRO outsourcing services. JOINN has built a thorough quality management system complying with international standards: CNAS/ILAC-MRA certification, NMPA, US FDA, OECD, Japan PMDA and Korean MFDS GLP certification and international AAALAC accreditation. JOINN provides customized services to the sponsor's specific needs for non-clinical safety assessments, clinical trials, registrations, and pharmacovigilance, covering the entire spectrum from development to final drug registration.

JOINN Laboratories 是一家专注于提供药物研发 CRO 外包服务的公司。公司建立了完善的符合国际标准的质量管理体系 :CNAS/ILAC-MRA 认证、NMPA、美国 FDA、OECD、日本 PMDA、韩国 MFDS GLP 认证和国际 AAALAC 认证。JOINN 针对申办者在非临床安全性评估、临床试验、注册和药物警戒等方面的特定需求，提供定制化服务，涵盖从开发到最终药物注册的整个范围。

地址：江苏省太仓市生物医药产业园昭溪路 1 号（昭衍（苏州）新药研究中心有限公司）
ADD：No. 1, Zhaoxi Road, Bio-pharmaceutical Industrial Park, Taicang City, Jiangsu Province (JOINN Laboratories (Suzhou) Co., Ltd.)
电话 /Tel：+86-10-67869966
邮箱 /E-mail：info@joinnlaboratories.com
网址 /Website：www.joinnlabs.com

Laviana 2275-F

Laviana Pharma Co., Ltd.
乐威医药（江苏）股份有限公司

地址：江苏省姜堰市经济开发区鸡鸣西路 222 号
ADD：No. 222, West Jiming Road, Jiangyan Economic Development Zone, Jiangyan City, Jiangsu Province, P. R. China
电话 /Tel：+86-523-88816128
邮箱 /E-mail：bd@lavianacorp.com
网址 /Website：www.lavianacorp.com

Founded in 2003, Laviana Pharma defines itself as a technology-driven enterprise focusing on innovative drug process research and manufacture outsourcing(CDMO). Laviana Pharma covers the whole process of pharmaceutical services (CMC) from laboratory to commercialization of small-molecule innovative drugs, including: process research, pilot-scale manufacturing and commercialization of APIs, starting materials for registration, and pharmaceutical intermediates from preclinical to approval, and approval services during the development.

乐威医药创建于 2003 年，是技术驱动型创新医药研发与生产服务（CDMO）企业。主要服务涵盖小分子创新药从实验室到商业化的药学服务全过程（CMC），包括：原料药、注册起始物料及医药中间体从临床前到上市的工艺研究、中试生产和商业化生产服务，以及开发过程中的报批服务。

NOVOTECH™
The Asia Pacific CRO

2275-G

Novotech Clinical Services (Shanghai) Co., Ltd
诺为泰医药科技（上海）有限公司

Novotech is internationally recognized as the leading Asia Pacific centred Biotech Contract Research Organization (CRO) with global execution capabilities.
Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 3000 staff globally and 34 office locations.

Novotech 立足亚太、面向全球，是专业的生物技术合同研究组织 (CRO)。

Novotech 是一家包含实验室、Ⅰ期临床中心、药物开发咨询服务和专业 FDA 法规服务的临床 CRO，拥有超 5,000 项临床项目经验，包括Ⅰ期至Ⅳ期临床试验。Novotech 专注于服务在亚太、美国与欧洲等地进行临床试验的生物技术客户。Novotech 目前在全球 34 个办公地点共拥有 3000 多名员工。

地址：上海市黄浦区黄陂南路 838 号中海国际中心 A 座 801 室
ADD：Room 801, Tower A, China Overseas International Centre | No. 838 South Huangpi Road, Shanghai
电话 /Tel：+86-21-53687666
传真 /Fax：+86-21-53687601
邮箱 /E-mail：info.cn@novotech-cro.com
网址 /Website：novotech-cro.com

药源新地 INNOLAND BIOSCIENCES

2275-H

Innoland Biosciences
苏州药源新地生物科技有限公司

地址：江苏省苏州市太仓市北京西路 6 号科技创业园主楼东 400
ADD：6 west Beijing Road, East building,400,Taicang City,Jiangsu Province,China
电话 /Tel：+86-512-53370999
邮箱 /E-mail：international_bd@innolandbio.com
网址 /Website：www.innoland.bio

LnnolandBio [Suzhou] was founded in 2021 and is mainly engaged in pre-clinical CRD service. The predecessor of lnnolandBio [Suzhou] was the Cardiovascular and Metabolic Diseases Depart ment of CrownBio Ltd. The very same team has 12 years of experience in pre-clinical pharmacological efficacy and toxicological evaluation, especially in the field of cardiovascular and metabolic diseases, and has been well recognized by world-renowned pharmaceutical companies. lnnolandBio [Suzhou] now has the world's largest cohort of non-human primates with spontaneous diabetes, and has established various animal models of diabetes complications, eye diseases and aging related diseases, etc. lnnolandBio is dedicated to continuously provide high quality service to the global pharmaceutical research and development.

苏州药源新地生物科技有限公司成立于 2021 年，主营临床前药理药效毒理实验外包业务。其前身为中美冠科心血管及代谢疾病部。该团队在临床前药理毒理评价尤其是在心血管和代谢疾病领域拥有超过 12 年的丰富经验，受到了包括 AZ, JNJ, Merck 等世界知名医药企业认可。苏州药源新地拥有世界最大的自发性糖尿病非人灵长类实验动物群，建立了糖尿病并发症、眼疾、老年疾病等多种动物模型，并将利用多年积累的经验和技术，为合作伙伴提供更加优质的服务。

Eminence 2275-I

Eminence Biotechnology (Suzhou) Co., Ltd.
艾米能斯（苏州）生物科技有限公司

Eminence is committed to developing and manufacturing high-quality CHO chemically defined media and providing tailor-made cell line and media formulation development services to clients around the globe working in the life science industry.
With a dedicated team and proprietary technology, Eminence has commercialized products for CHO-K1, CHO-S, CHO-DG44, HEK 293 and other cell lines, supporting and collaborating with clients to improve the performance.

艾米能斯专注于为全球生命科学领域提供化学成分限定培养基，定制化的细胞株开发和配方开发服务。

凭借专业的团队和自主专利技术，艾米能斯已上市了适用于 CHO-K1, CHO-S, CHO-DG44, HEK 293 等细胞系的培养基产品，支持客户不断提高蛋白质量和表达量。

地址：江苏苏州市苏州工业园区桑田街 218 号 24 号楼 3 层
ADD：218 Sangtian Street, 3F, Building 24, Suzhou Industrial Park, Jiangsu
电话 /Tel：+86-13771816415
邮箱 /E-mail：fiona.peng@eminencebio.com
网址 /Website：www.eminencebio.com

Medicilon 2275-J

Shanghai Medicilon Inc.
上海美迪西生物医药股份有限公司

地址：上海市浦东新区川大路 585 号（总部）
ADD：585 Chuanda Rd, Pudong, Shanghai, China, 201299 (Headquarters）1 Broadway, 9th Fl, Cambridge Innovation Center, Cambridge, MA 02142, US (US office)
电话 /Tel：+1-626-9869880
传真 /Fax：+86-21-58596369
邮箱 /E-mail：wswang@medicilon.com.cn
网址 /Website：www.medicilon.com

Medicilon is a professional pharmaceutical preclinical integrated R&D service contract research organization (CRO), providing a full range of one-stop new drug R&D services, in compliance with Chinese and international filing standards, to pharmaceutical companies and research institutions around the world. Our services cover the entire process of preclinical new drug research, including drug discovery, pharmacology research and preclinical research.
We focus on the needs of innovation and development of global pharmaceutical industry, based on the key aspects of R&D of innovative drug, and build a comprehensive technology platform covering drug discovery, pharmacological research and preclinical research key technologies with our rich experience in serving the Chinese and international biopharmaceutical industry.
For enquiries, please visit our website www.medicilon.com or email marketing@medicilon.com.

美迪西（股票代码：688202.SH）成立于 2004 年，总部位于上海，致力于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研究服务。美迪西的一站式综合服务以强有力的项目管理和更高效、高性价比的研发服务助力客户加速新药研发进程，服务涵盖医药临床前新药研究的全过程，包括药物发现、药学研究及临床前研究。至 2022 末，美迪西已为全球超 1840 家客户提供药物研发服务，参与研发完成的新药及仿制药项目已有 330 件 IND 获批临床，与国内外优质客户共同成长。美迪西将继续立足全球视野，聚力中国创新，为人类健康贡献力量！

2275-K

Taizhou Overseas Pharmaceuticals Co.,Ltd
泰州越洋医药开发有限公司

1. A leading Controlled Release DDS company with a focus to enhance the value of your existing assets (LCM) by offering superior efficacy and safety profiles, convenient to use, extended IP production, and combination products.
2. 12 years product development effort resulted in rich post-PoC pipelines for your fast commercialization.
3. About 200 Subject-Matter-Experts and Scientists globally to help fulfill your unment needs.
4. We can offer clinical trial material (CTM) manufacturing in both US and China.

公司专注缓控释 DDS 技术及产品开发，经过十余年的深耕细作，稳健发展，产品管线进入收获期。

截止 2023 年 5 月，越洋医药二类新药获批临床试验许可数量全国第三，其中口服固体缓控释新药获批临床批件 25 件（占全国总数一半，全国排名第一）；28 个新药获批美国 IND，7 个新药进入临床Ⅰ期；新药维安 ® 已完成 506 名患者的 III 期国际多中心临床试验。已有缓控释产品获得美国 FDA 批准上市并进入药店销售。越洋医药与上海医药、康缘药业、常州制药、天津医药等签署了数亿元针对中美市场的产品合作研发及生产销售协议。

地址：江苏省泰州市中国医药城陶弘景路 8 号双子楼 D 栋 703 室
ADD：7th Floor, National Business Incubator, China Medical City, Taizhou, Jiangsu,China, 225300
电话 /Tel：+86-18618485131
邮箱 /E-mail：cheryl.li@overseaspharm.com
网址 /Website： www.overseaspharm.com

2275-L

Bio-Link Biological Applied
百林科医药科技（上海）有限公司

地址：上海市浦东新区城丰路 650 号 A 座、B 座
ADD：Block A & B, No. 650 ChengFeng Road, PuDong New Area, Shanghai , China
电话 /Tel：+00491729943881
邮箱 /E-mail：biao.zhang@biolink-global.com
网址 /Website： www.biolink.com

Bio-Link is a group of technology-driven businesses that provide products and process solutions in the life sciences industry. The company focuses on the development and production of the key processing equipment and materials for vaccines, antibodies, cell therapies, gene therapies and other biological products. Bio-Link's portfolio of offerings:

- Fluid management
- Chromatography purification
- Filtration and ultrafiltration
- Process development & validation services

Bio-Link is committed to providing customers with high-quality, innovative products and solutions and strives to build an efficient, safe and competitive biopharmaceutical supply chain eco-system.

百林科医药科技（上海）有限公司（以下简称百林科）是一家为生命科学领域提供工艺解决方案的高新科技集团化企业，专注于疫苗、抗体药物、细胞治疗、基因治疗及其它生物制品关键工艺设备与耗材的研发和制造，产品涵盖生物工艺一次性配储液和下游层析、超滤、过滤等工艺单元和工艺开发服务。百林科致力于持续为客户提供高品质创新产品和解决方案，打造高效、安全和有竞争力的生物制药供应链生态圈。

TransThera 药捷安康 2275-M

TransThera Sciences (Nanjing), Inc.
药捷安康（南京）科技股份有限公司

About TransThera Sciences, Inc. – Developing Transformative Therapies for Patients Worldwide:
TransThera Sciences, Inc., headquartered in Nanjing, is an R&D-driven, clinical-stage biopharmaceutical company focusing on discovery and development of innovative and highly differentiated NCE drugs targeting the significant unmet medical needs in oncology, inflammatory, and cardiovascular diseases.
TransThera has a strong leadership team with extensive experience from global pharmaceutical and biotech companies, including Merck, BMS and Roche, etc. TransThera is unique with agile and dynamic characteristics as delineated below:

- Proprietary “ACE” platform to generate Differentiated Drug-like NCE Drugs
- 7 clinical molecules delivered within 6 years
- Efficient and Experienced Clinical & Regulatory Team with high productivity and solid delivery
- Strong and Diverse Pipeline with Global Clinical Development Programs
  - o Close cooperation with leading PIs in prestigious medical institutions
  - o Solid engagement with KOLs
  - o Excellent working relationship with regulatory authorities
- Broad global collaborations with partners from the US, Europe, South Korea, and Japan
- Diversified shareholders with a strong Global Network

关于药捷安康（南京）科技股份有限公司 – 为全球患者开发变革性治疗方案：

药捷安康（南京）科技股份有限公司，总部位于南京，是一家以研发为驱动的临床阶段生物制药公司，专注于发现和开发创新及高度差异化的新分子实体药物，以满足肿瘤，炎症和心血管疾病中重要的未满足临床需求。

药捷安康拥有一支强大的领导团队。领导层成员具有包括默克，百时美施贵宝和罗氏等国际制药公司和生物技术公司的丰富工作经验。药捷安康的优势与差异化在于：

- 专有的“ACE”平台，用于研发具有差异化且成药性高的新分子实体药物
- 6 年内推动 7 个产品进入临床开发阶段
- 高效且经验丰富的临床和注册团队推进项目的临床开发
- 基于全球视野的临床开发体系以支撑丰富且多样化的管线
  - o 与知名医疗机构的顶尖 PI 密切合作
  - o 与 KOL 的密切互动
  - o 与监管机构保持了良好的交流与沟通
- 与美国、欧洲、韩国和日本的合作伙伴进行广泛的全球合作
- 具有丰富国际资源的多元化股东结构

地址：南京市江北新区生物医药谷加速器二期 9 栋 3 楼
ADD：F3, Bld 9, Accelerator Phase 2, Biotech and Pharmaceutical Valley, Jiangbei New Area, Nanjing, China, 210032
电话 /Tel：+86-18795998802
邮箱 /E-mail：bd@transtherabio.com
网址 /Website：www.transthera.com

innoforce 2275-N

Innoforce Pharmaceuticals
浙江健新原力制药有限公司

地址：浙江省杭州市临空经济示范区坎红路杭州生物科技谷
ADD：No.376 Fengtu Street, Xiaoshan District, Hangzhou, China
电话 /Tel：+86-571-82816679
邮箱 /E-mail：cdmo@innoforcepharma.com
网址 /Website：www.innoforcepharma.com

Innoforce enables the innovation and global supply of plasmid DNA, RNA, cell and gene therapeutics, powered by a world-class manufacturing and development hub. With extensive expertise in process development and manufacturing of Advanced Therapy Medical Products (ATMPs), Innoforce can be a trusted partner for your innovative ATMP projects from R&D through commercialization.

健新原力聚焦于 RNA、细胞和基因治疗制品领域，致力于为先进疗法药物合作伙伴提供包括质粒、病毒载体、细胞治疗产品、RNA 在内的一站式 CDMO 解决方案。健新原力团队在工艺开发、临床及商业化 GMP 生产、LNP 包封和无菌灌装、项目管理及申报等领域拥有丰富经验，是您值得信赖的先进疗法合作伙伴。

2275-0

Yaohai Bio-Pharmaceutical Co.,Ltd
江苏耀海生物制药有限公司

Yaohai Bio-Pharma is China's first and largest biologics CRDMO (Contract Research, Development and Manufacturing Organization) focusing on microbial expression systems. It provides customized end-to-end solutions from DNA design and synthesis, microbial strain engineering and construction to drug substance manufacturing in GMP or non-GMP level and products fill & finish across diversified modalities, such as recombinant proteins, peptides and polypeptides, enzymes, single-domain antibodies (sdAbs), plasmid DNA and mRNA, glyco-polymers, virus-like particles (VLPs), to meet global customers' clinical and commercial needs in biological drugs, biosimilars, vaccines and diagnostics for human and veterinary use.

Yaohai Bio-Pharma is actively building an alliance with independent and corporate partners to boost its international business development. Partners can leverage their industry connections to introduce relevant clients or new partners to the company, and the latter will offer commissions on any resulting business.

For more details about Yaohai Bio-Pharma, kindly refer to: www.yaohai-bio.com.cn

Key words: CRDMO, microbial expression systems, recombinant proteins, nucleic acid drugs, sdAbs, VLPs vaccines, microbial strain engineering and construction

耀海生物是中国第一家也是最大的生物制品 CRDMO（合同研究、开发和制造组织），专注于微生物表达系统。耀海生物提供从 DNA 设计和合成、微生物菌株工程和构建、GMP 或非 GMP 级别的药品生产和制剂工艺等多样化模式的定制端到端解决方案，包括重组蛋白、肽和多肽、酶、单域抗体（sdAbs）、质粒 DNA 和 mRNA、糖基聚合物、病毒样颗粒（VLPs）等，以满足全球客户在生物药品、生物仿制药、人用和兽用疫苗和诊断方面的临床和商业需求。耀海生物正在积极与独立个人和企业合作伙伴建立联盟，以促进国际业务的发展。合作伙伴可以利用其行业关系向公司介绍相关客户或新合作伙伴，我们将为任何产生的业务提供佣金。

关于耀海生物的更多细节，请参考：https://www.yaohai-bio.com.cn

关键词：CRDMO，微生物表达体系，重组蛋白，核酸药物，单域抗体，病毒样颗粒疫苗，大肠杆菌，酵母，微生物菌株工程和构建

地址：江苏省泰州市健康大道 801 号 27 幢（药城）
ADD：Building 27,No.801,Jiankang Road,Taizhou City,Jiangsu Province,China
电话 /Tel：+86-13671757565
邮箱 /E-mail：BD@yaohaibio.cn
网址 /Website：www.yaohai-bio.com.cn/downloadfile

2275-P

Suzhou ExCell Biotechnology Co., Ltd.
苏州依科赛生物科技股份有限公司

地址：中国江苏省苏州市太仓市浮桥镇安江路 66 号
ADD：No. 66, Anjiang Road, Fuqiao Town, Taicang City, Suzhou City, Jiangsu Province, China
电话 /Tel：+86-15900582675
传真 /Fax：+86-8621-33676258
邮箱 /E-mail：guhaiying@excellbio.com
网址 /Website：www.genetimes.com.cn

As a leader in Life Science Reagents and Biopharmaceutical critical materials in China, ExCell Bio group has more than 20 years experience in this field. We are the first member of International Serum Industry Association(ISIA) in China and provide high-quality products and services of cell culture medium. Our headquarter is located in China and branch companies are spread to Uruguay, Australia and United States.

ExCell Bio specializes in the industry of Biopharmaceutical, Cell and Gene Therapy,Stem Cell and Scientific research. Our major product lines cover Fetal Bovine Serum, Serum free media (T, NK, CHO,HEK293, MSC) and Biosafety Analytical Kits.

We have an areas of 11000 ㎡ platform for R&D and GMP manufacture site with the capacity of 1000kg for dry powder and 500~2000L for liquid. At the same time, we have in house QC for every product, endeavoring to keep your experiment results more consistent and precise. Through unremitting effort and development, our customers have spread China market and any other countries all over the world.

ExCell Bio also offers custom services to meet the diverse needs of customers and their expectations.

依科赛生物（ExCell Bio）创立于 2013 年，以“加快生命科技应用，造福百姓健康”为使命，致力于解决生物医药卡脖子、实现关键原料国产化，现已成为中国生物医药上游核心原材料的领军企业之一。公司是国家高新技术企业，国家级专精特新小巨人企业、国家知识产权优势企业、省和苏州市独角兽培育企业、中国首家国际血清行业协会（ISIA）会员单位，江苏省生物制药、细胞治疗等领域用 CD 无血清培养基工程研究中心。

公司当前聚焦无血清培养基、胎牛血清和鉴定试剂等三大产品板块，为生物药、细胞与基因治疗、基础科学研究客户提供国际品质的产品与服务。公司依托国际化和专业化的研发技术团队、质量和生产团队以及商业化团队，持续创新，追求卓越，在不断优化产品性能的同时，确保可靠的质量和稳定的供应，全面赋能生物医药产业的快速健康发展，打造细胞培养“中国芯”产品。

HITGEN 2275-Q

HitGen Inc.
成都先导药物开发股份有限公司

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

成都先导药物开发股份有限公司（上海证券交易所股票代码：688222.SH，股票名称：成都先导）致力于打造全球一流的创新型生物医药企业，总部位于中国成都，在英国剑桥、美国休斯顿设有子公司。公司聚焦小分子及核酸新药的发现与优化，着力打造了 DNA 编码化合物库技术（包括 DEL 库的设计、合成和筛选及拓展应用）、基于分子片段和三维结构信息的药物设计技术（FBDD/SBDD）、寡聚核酸新药研发平台相关技术（STO）、靶向蛋白降解平台相关技术（TPD）等四个核心技术平台。通过新药研发服务、不同阶段在研项目转让以及远期的药物上市等多元化的商业模式，成都先导与全球数百家制药公司、生物技术公司、化学公司、基金会以及科研机构建立了合作。目前，公司有多个内部新药项目处于临床及临床前不同阶段。

地址：四川省成都市双流区（天府国际生物城）慧谷东一路 8 号 C2 栋
ADD：Building C2, No. 8 Huigu 1st East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan, China
电话 /Tel：+86-28-85197385
邮箱 /E-mail：bd@hitgen.com
网址 /Website：www.hitgen.com

博奥信 BIOSION 2275-R

Biosion,Inc.
博奥信生物技术（南京）有限公司

地址：南京市高新开发区新锦湖路 3-1 号中丹生态生命科学产业园二期 D 座 5 层
ADD：5th Floor Building D Zhongdan Unit South Longshan Rd Jiangbei New District Jiangsu China
电话 /Tel：+86-25-58291977
传真 /Fax：+86-25-86507191
邮箱 /E-mail：BD@Biosion.com
网址 /Website：www.biosion.com

Biosion is a clinical-stage global biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H^3 antibody discovery platform, SynTracer® high-throughput endocytosis platform, and Flexibody™ bispecific platform. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in Phase 2 for severe asthma and entering Phase 2 for atopic dermatitis. Biosion and partners have plans to progress additional immune-oncology biologics and antibody drug conjugates into clinical trials for oncology indications over the next three years. Biosion has operations in the US, Australia, and China.

博奥信是一家处于临床阶段的全球化创新生物技术公司，致力于应用专有的抗体技术平台开发创新疗法，使患者在免疫及肿瘤疾病的治疗中获益。成立于 2017 年，博奥信通过内部专有的 H^3 抗体发现平台、SynTracer® 高通量抗体内吞筛选平台、以及 Flexibody™ 双功能抗体技术平台及全球合作建立了一系列创新药物管线。自研产品 BSI-045B（抗 TSLP 单抗）正在中美开展针对严重哮喘与特应性皮炎的临床二期试验，未来三年内，博奥信及其合作伙伴会将更多的免疫肿瘤学生物制剂和抗体药物偶联物推向临床试验。博奥信在中国，美国与澳大利亚均设有分支机构。

SYNTHGENE 2285-A

Jiangsu Synthgene Biotechnology Co., Ltd.
江苏申基生物科技有限公司

Founded in 2018, Jiangsu Synthgene Biotechnology Co., Ltd. focuses on providing overall solutions for upstream raw materials in life sciences. The core members of the company are the chemical biology PhD team from Nanjing University. Academician Hongyuan Chen is chief scientist, who has strong technical background in chemical biology. Over the years, Synthgene is committed to the development and industrialization of life science insurmountable raw materials. Currently, Synthgene antibody discovery platform, mRNA stock solution preparation platform, mRNA-LNP preparation process platform, oligonucleotide preparation platform, enzyme directed evolution platform contribute to derivative three product segments include cell gene therapy raw materials, gene nucleic acid drug raw materials and IVD raw materials.

申基生物成立于 2018 年，专注于为客户提供生命科学领域上游原料的整体解决方案。公司核心成员源自南京大学化学生物学博士团队，首席科学家为陈洪渊院士，拥有极强的化学生物学技术背景，多年来致力于生命科学卡脖子原料的研发和产业化，现已具有抗体发现平台、mRNA 原液制备平台、mRNA-LNP 制剂工艺平台、寡核苷酸制备平台、酶定向进化平台等技术，在此驱动下，衍生细胞基因治疗原料、基因核酸药物原料以及 IVD 原料三大产品板块。

地址：江苏省南京市栖霞区纬地路 9 号江苏生命科技园 B6-2 幢申基生物
ADD：Building B6-2, No. 9, Weidi Road, Xianlin University Town, Xianlin Subdistrict, Qixia District, Nanjing City, China
电话 /Tel：+86-13951638454
邮箱 /E-mail：christina.hang@syngenebio.com
网址 /Website： en.syngenebio.com

Wilmington PharmaTech 2285-C

Wilmington PharmaTech Company LLC (WPT Suzhou)
广惠药业（苏州）有限公司

地址：苏州工业园区，星湖街 218 号，生物纳米园 C-19
ADD：C-19 Building, 218 Xinghu Street Suzhou Industrial Park Jiangsu, China
电话 /Tel：+86-512-69561818
传真 /Fax：+86-512-69561919
邮箱 /E-mail：chenlei@wptpharma.com
网址 /Website： http://wilmingtonpharmatech.com

Wilmington PharmaTech (Suzhou) is a full-service company specializing in chemical process research and development.
We provide contract process research, crystalline salt screen, polymorph screen, cGMP synthesis, bulk drug intermediates and analytical method development and validation for pharmaceutical and biotechnology companies.
Wilmington PharmaTech and Wilmington PharmaTech (Suzhou) operate two research centers from Delaware Technology Park and Pencader Corporate Center, Newark, Delaware, USA with multi cGMP kilo labs, a state of art process research center and bulk production facilities in Suzhou, China.

广惠药业（苏州）有限公司是一家为客户提供全面技术服务公司。专门从事新药生产工艺的研究和开发。

我们为大，中，小制药和生物技术公司提供技术咨询服务，生产过程改进，晶型问题的研究，原料药中间体和原料药的 cGMP 生产。

广惠药业在美国有 2 个研究中心，分别为 Delaware Technology Park 和 Pencader，并且有多个 cGMP 公斤级实验室，工艺研究中心；在中国苏州有更大的生产基地。

2285-D

Sunresin New Materials Co. Ltd.
西安蓝晓科技新材料股份有限公司

Sunresin, headquartered in Xi'an, China, is listed on the Shenzhen Stock Exchange with a stock code of 300487. The company's total market value is approximately US$4.5 billion. It is an innovative high-tech enterprise. Focus on R&D and innovation more than 22 years, and constantly introduce new technologies, new processes, and new products to promote the industrialization of different fields. The company already has 3 overseas branch offices, as well as 5 state-of-the-art manufacturing facilities around the world. Sunresin is becoming a global leader in resins and services and specialized in manufacturing and supplying of Monojet Ion exchange resins, Special adsorbent resins, Chromatography resins, SPPS resins, Chelating resins, Engineering system & services provider etc.

In the field of life sciences, the company has made great progress. Establishing four GMP-like production workshops in China, and strictly controls the production process in accordance with ISO quality management system. The products are in complete range, mainly including microcarriers, agarose/dextran chromatography resins, polymer resins, peptide synthesis carriers, enzyme carriers. Applied to upstream cell culture of biopharmaceuticals, and downstream Mabs, mRNA, vaccines, proteins, peptide, biological small molecules purification, oligonucleotide synthesis, and in vitro diagnostic reagents.

Sunrein is committed to providing cost-effective chromatographic resins with high quality and excellent performance to serve world biopharmaceutical clients.

蓝晓科技（300487，深圳），分离纯化填料领域的跨国企业，主营业务为吸附分离材料研发、生产和销售，提供以吸附分离材料为核心的配套系统装置和整体解决方案。

公司是国家重点高新技术企业，中国离子交换树脂行业副理事长单位，国家科技进步二等奖获得者。

公司全球下设九个控股、参股分公司，以及三个业务发展中心，年产树脂 5 万立方米，提供各类分离装置百余套，拥有员工超过千人。

地址：西安市高新区锦业路 135 号蓝晓科技园
ADD：Sunresin Park, No. 135 Jinye Rd, Xi'an Hi-tech Industrial Development Zone, Shaanxi, China
电话 /Tel：+1-979-450-0778
邮箱 /E-mail：jian.liu@sunresin.com
网址 /Website：www.seplite.com

2285-E

MITRO Biotech Co., Ltd
米度（南京）生物技术有限公司

地址：江苏省南京市江宁区乾德路 5 号 8 号楼
ADD：Building 8, No.5 Qiande Road, Jiangning Science Park, Nanjing
电话 /Tel：+86-15151861828
邮箱 /E-mail：wangpu@mi-tro.com
网址 /Website：www.mi-tro.com

MITRO, founded in 2012, is the first molecular imaging CRO company in China.

By applying Radiolabeling and Molecular Imaging techniques, MITRO provides outstanding services including preclinical and clinical drug screening, bio-distribution, pharmacokinetics and pharmacodynamics. MITRO can provide one-stop service for radiopharmaceuticals including in vitro discovery, radiochemistry, pre-clinical study, clinical study and registration.

米度（南京）生物技术有限公司成立于 2012 年，是中国首家分子影像 CRO 公司。

通过应用放射性标记和分子影像技术，米度生物可以提供卓越的服务，包括临床前和临床的药物筛选、生物分布、药代动力学和药效学研究。米度生物可以为放射性药物提供从早期开发、药学研究、临床前研究、临床研究及注册申报的一站式服务。

CIMC北京中集 2285-F

Beijing CIMC Lengyun technology Co. Ltd.
北京中集冷云科技有限公司

Beijing CIMC Lengyun technology Co. Ltd. is a leading global innovator and provider of passive tempera¬ture control packaging solutions for the pharmaceutical, life science and cold chain logistics industries
Whilst we may be a relatively new name in the pharmaceutical market, our expertise and experience date back to 2012 when we started to supply high quality medi¬cal refrigeration to the China market. Since then, our business has grown year-on-year. Till now, CIMC Lengyun has provided cold chain service for over 200 million vials of COVID-19 vaccines' export.
Exciting new products continue to be developed as CIMC Lengyun pushes for greener solutions. Further¬more, CIMC Lengyun allow for flexability in purchasing solutions and en¬abling the reuse of packaging, re¬ducing waste and costs.
These and other developments have all been products of our com¬mitment to listening to our clients, being responsive to their needs - and often anticipating their needs before they arise.

北京中集冷云科技有限公司是全球领先的被动式温度控制包装解决方案提供商和创新者，专为制药、生命科学和冷链物流行业提供服务。

虽然我们在制药市场上是一个相对较新的品牌，但我们的专业知识和经验可以追溯到 2012 年，当时我们开始向中国市场供应高品质的医疗制冷设备。从那时起，我们的业务逐年增长。截至目前，中集冷云已为超过 2 亿支 COVID-19 疫苗提供冷链服务。

中集冷云在推动更环保的解决方案方面不断开发令人兴奋的新产品。此外，中集冷云允许灵活采购解决方案并实现包装的重复使用，减少浪费和成本。

这些和其他发展成果都是我们致力于倾听客户需求、快速响应客户需求并常常预见客户需求的承诺的产物。

地址：北京市顺义区南彩镇彩达三街一号茂华工场 1 号厂房 2 层 201
ADD：201，building 1, Maohua Industrial Park, Caida 3rd street, Nancai Town, Shunyi District, Beijing, China
电话 /Tel：+86-18721913659
邮箱 /E-mail：hefengli@cccc58.com
网址 /Website： https://cimcthermal.com

THERO° 2285-G

Shenzhen Thero New Material Technology Co.Ltd
深圳市森若新材科技有限公司

地址：深圳市福田区深南大道 6002 号 501
ADD：6002-501 Shennan Avenue,Shenzhen
电话 /Tel：+86-755-86387006
传真 /Fax：+86-755-86387006
邮箱 /E-mail：nancy@theromaterial.com
网址 /Website：www.theromaterial.com

Thero is a phase change material (PCM) R&D company, manufacturing PCM, cold boxes and thermal modules for the cold chain transportation and the cold room/conditioner. We devote ourselves to the best use of the thermal energy and facilitate reduce the carbon emissions.
Temperature is critical to the product quality. The global warming makes the temperature sensitive product delivery a challenging task, Thero aim to reduce the hassles of temperature-safe transportation. We develop our own TEMPCORE™ materials, design the recycle boxes for the best quality of 10 days and PLUS delivery. Partnering with Thero is a peace of mind temperature-controlled decision. Thero provide CONSTEMP™ cold boxes at a stable temperature for 5 days to 21 days. The cold boxes pipeline includes 16L to 3000L boxes with temperature choices from 21°C, 5°C, 0°C, -15°C, -18°C, -20°C, -67°C etc. Customization is welcome.
The cold room modules provide a quick installation without disturbing the routines, while storing the energy during nighttime and transferring the regenerative energy to designed modules for cold room or air conditions. The cold room use the energy storage module not only save the energy use but also cut the bill.

Thero 是一家相变材料 (PCM) 研发公司，致力于热能的最佳利用，贡献碳排放的减少。目前应用於冷链运输、冷库和空调系统，生产制造相变材料 (PCM)、冰排、冷链箱和热能模块。

温度对产品质量至关重要，全球暖化使得温度敏感产品运输成为一项具有挑战性的任务，Thero 旨在减少温度安全运输的麻烦。我们开发自己的 TEMPCORE™ 材料，设计可循环冷链箱，以实现 10 天以上的最佳质量，客户与 Thero 合作是一个心安的温度控制决定。Thero 销售可控温 5 天至 21 天、温度稳定的 CONSTEMP™ 冷链箱，箱体有效使用容积从 16L 到 3000L；温度可控制在 21°C、5°C、0°C、−15°C、−18°C、−20°C、−67°C 等，我们接受定制贵司所需的大小与温度。

冷库或空调系统使用预制好的储能模块，可在不干扰常规的情况下快速安装，同时储能模块可以移峰填谷在夜间储存能量，或储存可再生能量，既节省了能源的使用，又节省了电费。

JenKem Technology 键凯科技 股票代码 688356.SH

2285-H

JenKem Technology Co., Ltd.
北京键凯科技股份有限公司

Serving your PEG and PEGylation needs from laboratory through GMP commercial scale!
In business for over 21 years, JenKem Technology specializes in high-purity, low polydispersity polyethylene glycol (PEG) derivatives, PEG co-polymers, monodisperse PEGs, custom PEG derivative synthesis and PEGylation services. JenKem Technology supplies PEG derivatives worldwide, from R&D through GMP commercial quantities, for preclinical, clinical trials, and commercial products in the pharmaceutical, biotechnology, medical device, and diagnostics marketplaces.
ISO 9001 and 13485 certified, following ICH Q7 GMP guidelines.
JenKem Technology's PEG derivatives are used in a growing number of applications, including PEGylation of peptides, proteins, oligonucleotides, and small molecules, the formation of hydrogels, lipid nanoparticles, controlled release drug delivery, gene delivery, click chemistry, 3D BioPrinting, PROTAC and ADC linkers.
Functionally, JenKem Technology's PEG products include activated PEG derivatives for amine PEGylation, activated PEG derivatives for N-terminal PEGylation, activated PEG derivatives for C-terminal PEGylation, and activated PEG derivatives for thiol PEGylation. Structurally, JenKem Technology's PEG products include Y-shaped and branched PEG derivatives, linear methoxy PEGs, homobifunctional PEGs, heterobifunctional PEGs, multi-arm homofunctional and heterobifunctional activated PEGs, monodisperse (discrete) PEGs, Biodegradable PEG Co-Polymers (such as PEG-PLGA, PEG-PLA, PEG-PCL, and other), and PEG GPC Standards.
JenKem Technology's services include custom synthesis of PEG derivatives in small scale and GMP commercial amounts, and custom PEGylation.
Please contact us at sales@jenkemusa.com or 1-866-953-6536 and visit our website at www.jenkemusa.com for more details on our PEG products and PEG-related services.

北京键凯科技股份有限公司（688356.SH）是致力于医用药用聚乙二醇衍生物产业化的高新技术企业，是国内外为数不多能进行高纯度和低分散度的医用药用聚乙二醇及活性衍生物工业化生产的公司。键凯科技拥有高纯度 PEG 原料研制技术平台、医用药用 PEG 材料平台、PEG 医药应用创新平台等 3 个核心技术平台，实现了从 PEG 原料、PEG 衍生物到 PEG 修饰药物研制的全面覆盖。键凯科技支持中国境内 4 个已上市的聚乙二醇修饰药物的研发和生产，3 个已上市的国际医疗器械产品及一款商业化的国际药物端产品，同时还支持了多家国内国际药企及医疗器械企业的数十个 II、III 期临床项目。

地址：北京市海淀区西小口路 66 号 C1 楼三层北京键凯科技股份有限公司
ADD：4105 W. Spring Creek Pkwy, #606B, Plano, TX 75024, USA
电话 /Tel：+01-972-6730603
传真 /Fax：+01-469-3272615
邮箱 /E-mail：sales@jenkemusa.com
网址 /Website：www.jenkemusa.com

chime BIOLOGICS

2285-I

Chime Biologics
鼎康生物

地址：湖北省武汉市东湖新技术开发区高新二路 388 号
ADD：388 Gaoxin Road (No.2)East Lake Hi-tech Development Zone Wuhan, Hubei Province, PRC.
电话 /Tel：+86-13817932336
邮箱 /E-mail：swang@chimebiologics.com
网址 /Website：https://chimebiologics.com

Chime Biologics is a leading CDMO with the world's first modular biopharmaceutical factory, KUBio. It empowers the entire biologics processes – from cell line development to commercial manufacturing. Chime Biologics provides one-stop CMC solutions to worldwide biomedical customers, relying on cell line development and advanced technology development from its Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan campus. We share a common goal to make cutting-edge biologics affordable and accessible to all patients globally, fulfilling its commitment to human health.

鼎康生物是一家专业的 CDMO 公司，率先引进了全球首个模块化生物制药工厂 KUBio，赋能生物制品从细胞株开发到商业化生产的全过程。我们位于上海的创新中心聚焦高效的细胞株开发和先进的技术开发，与拥有多国临床试验申请和新药上市成功经验的武汉制造工厂相结合，鼎康生物正在为全球生物医药客户提供一站式的 CMC 解决方案。在鼎康生物，我们有一个共同的目标，致力于提高前沿生物医药对全球患者的可及性，履行我们对人类健康的承诺。

中国国际商会

China Chamber of International Commerce